Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Keymed Biosciences Inc.
  6. Summary
    2162   KYG5252B1023

KEYMED BIOSCIENCES INC.

(2162)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Hong Kong Stock Exchange
11/29/2021 11/30/2021 12/01/2021 12/02/2021 12/03/2021 Date
51.5 47.3 46.5 46.05 48.8 Last
859000 1604000 352500 152500 566000 Volume
+2.49% -8.16% -1.69% -0.97% +5.97% Change
Estimated financial data (e)
Sales 2021 35,0 M 5,49 M 5,49 M
Net income 2021 -2 126 M -333 M -333 M
Net cash position 2021 3 396 M 533 M 533 M
P/E ratio 2021 -5,25x
Yield 2021 -
Sales 2022 75,0 M 11,8 M 11,8 M
Net income 2022 -443 M -69,4 M -69,4 M
Net cash position 2022 2 680 M 420 M 420 M
P/E ratio 2022 -25,2x
Yield 2022 -
Capitalization 11 167 M 1 751 M 1 752 M
EV / Sales 2021 222x
EV / Sales 2022 113x
Nbr of Employees 211
Free-Float 57,7%
More Financials
Company
Keymed Biosciences Inc is a China-based biotechnology company. The Company focuses on the independent discovery and development of innovative biological therapies that address underserved medical needs in the autoimmune and oncology therapeutic areas. The Company has mastered in-house drug discovery and development technologies, including an innovative antibody discovery platform and a proprietary novel T cell... 
More about the company
All news about KEYMED BIOSCIENCES INC.
12/01Keymed Biosciences Chairman, Controlling Shareholder Ups Stake in Firm
MT
11/30Keymed's Atopic Dermatitis Treatment Shows Positive Results in Clinical Trial
MT
11/29Keymed Biosciences Inc. Announces Positive Results from Cm310 Atopic Dermatitisphase II..
CI
11/21CSPC Pharma Strikes Licensing Deal for China Rights to Keymed Bio's Allergy Drug
MT
11/05Keymed Biosciences' Asthma, Atopic Dermatitis Treatment Gets Positive Results in Phase ..
MT
11/04Keymed Biosciences Inc. Announces Positive Results from Phase I Clinical Study of CM326
CI
09/22KEYMED BIOSCIENCES : Partners With CSPC Pharmaceutical to Develop Potential Nervous System..
MT
09/01KEYMED BIOSCIENCES' : H1 Loss Expands
MT
08/31Keymed Biosciences Inc. Announces Unaudited Consolidated Earnings Result for the Six Mo..
CI
08/02KEYMED BIOSCIENCES : Bio Raises Nearly $58 Million from Full Exercise of Hong Kong IPO's O..
MT
07/07Keymed Biosciences Inc. has completed an IPO in the amount of HKD 3.105498 billion.
CI
06/25Keymed Biosciences Inc. has filed an IPO in the amount of HKD 3.105498 billion.
CI
More news
News in other languages on KEYMED BIOSCIENCES INC.
11/21CSPC Pharma conclut un accord de licence pour les droits chinois sur le médicament cont..
09/01La perte de Keymed Biosciences au premier semestre s'accentue
More news
Chart KEYMED BIOSCIENCES INC.
Duration : Period :
Keymed Biosciences Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KEYMED BIOSCIENCES INC.
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 39,92 CNY
Average target price 63,79 CNY
Spread / Average Target 59,8%
EPS Revisions
Managers and Directors
Bo Chen Chairman & Chief Executive Officer
Yanrong Zhang Chief Financial Officer & Co-Secretary
Xiao Fan Wang Independent Non-Executive Director
Cheuk Kin Law Independent Non-Executive Director
Yang Ke Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
KEYMED BIOSCIENCES INC.0.00%1 751
GILEAD SCIENCES, INC.19.40%87 255
BIONTECH SE310.30%83 098
REGENERON PHARMACEUTICALS31.23%66 409
WUXI APPTEC CO., LTD.26.31%65 758
VERTEX PHARMACEUTICALS-13.76%51 819